Modulation of T-cell response to phospholipase A2 and phospholipase A2–derived peptides by conventional bee venom immunotherapy Regine Kämmerer, MDa,b,

Slides:

Advertisements

Similar presentations

Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus-infected insect cells as compared with Escherichia.

Advertisements

Yvan Boutin, PhD, Jacques Hébert, MD

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

In vitro lymphocyte proliferation with milk and a casein–whey protein hydrolyzed formula in children with cow's milk allergy Philippe A. Eigenmann, MD,

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Catherine M. Counsell, MAa, Julian F. Bond, PhDa, John L

Evaluation and treatment of allergic fungal sinusitis. II

Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis Teruo Shiomori, MDa, Shin-ichi Yoshida, MD, PhDb,

Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison.

The effects of upper respiratory infection on T-cell proliferation and steroid sensitivity of asthmatics Elcio O. Vianna, MD, PhD, Jay Westcott, PhD,

Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE Eva-Maria Varga, MD, Fahima Kausar, MSc, Werner.

Catherine M. Counsell, MAa, Julian F. Bond, PhDa, John L

Erika Lerch, MD, Ulrich R. Müller, MD

Evaluation and treatment of allergic fungal sinusitis. II

In vitro lymphocyte proliferation with milk and a casein–whey protein hydrolyzed formula in children with cow's milk allergy Philippe A. Eigenmann, MD,

Dose-dependent effects of capsaicin nasal challenge: In vivo evidence of human airway neurogenic inflammation Alvin M. Sanico, MDa, Satsuki Atsuta, MDa,

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-γ production in CD4+ T cells Gideon Lack, MD, Harold.

Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma Malgorzata Pierzchalska,

Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD

Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma B.Lauren Charous, MD, Elkan F. Halpern,

Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.

Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen,

Elephantiasis nostras: A case report

Paul Van Durme, MDa, Jan L. Ceuppens, MD, PhDa,b, Pascal Cadot, PhDb

Socioeconomic status and race as risk factors for cockroach allergen exposure and sensitization in children with asthma Sampson B. Sarpong, MDa, Robert.

Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effects of single allergen challenge Adriaan.

News & Notes Journal of Allergy and Clinical Immunology

Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: Conversion with immunotherapy and relation to.

Allergens in school dust: II

Modulating allergic response by engineering the major Parietaria allergens Angela Bonura, PhD, Daniela Di Blasi, PhD, Bianca Barletta, PhD, Cinzia Butteroni,

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Epithelial cells as regulators of airway inflammation

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Priscilla Auyeung, PhD, Diana Mittag, PhD, Philip D

Allergy to cooked white potatoes in infants and young children: A cause of severe, chronic allergic disease Liliane F.A. De Swert, MD, Pascal Cadot,

Mary Elizabeth Bollinger, DO, Robert G. Hamilton, PhD, Robert A

Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms Aaron M. Levy, MDa, Hirohito Kita, MDb, Sidney F. Phillips, MDa, Paul.

Ganglioside GQ1b enhances Ig production by human PBMCs

Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcϵRI or anti-IgE autoantibodies

News & Notes Journal of Allergy and Clinical Immunology

Api m 6: A new bee venom allergen

Increased expression of the CD80 accessory molecule by alveolar macrophages in asthmatic subjects and its functional involvement in allergen presentation.

Human monoclonal or polyclonal antibodies recognize predominantly discontinuous epitopes on bee venom phospholipase A2 Theres Schneidera, Alois B. Lang,

Modulation of T-cell response to phospholipase A2 and phospholipase A2–derived peptides by conventional bee venom immunotherapy Regine Kämmerer, MDa,b,

Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy Véronique Schulten, PhD,

Sarbjit S. Saini, MDa, Jennifer J

Fetal and neonatal IL-13 production during pregnancy and at birth and subsequent development of atopic symptoms Toby J. Williams, Catherine A. Jones,

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Harald Renz, MD, Chaya Brodie, PhD, Katherine Bradley, BS, Donald Y. M

Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells Véronique Schulten, PhD, Victoria Tripple, BSc, Grégory Seumois,

Thomas E. Van Metre, MD, Gary L. Rosenberg, MD, Surender K

G. Weyman Price, MDa, b, Angela D. Hogan, MDc, A. Holly Farris, BAa, A

Prognosis and prediction of response to surgery in allergic patients with chronic sinusitis François Lavigne, MDa, Cong Thu Nguyen, MDa, Lisa Cameron,

The potential clinical utility of serum α-protryptase levels

Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen Catherine.

Anaphylaxis after initial ingestion of rambutan, a tropical fruit

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Changes in sputum counts and airway hyperresponsiveness after budesonide: Monitoring anti-inflammatory response on the basis of surrogate markers of airway.

Penicillium nalgiovense as an occupational and contact allergen

Jonathan M. Corne, MRCPa, Catherine H. Linaker, BNa, Peter H

Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trial Jean-Marc Fellrath, MDa, Alexander.

Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin- induced asthma Yukio Kawagishi, MDa,b, Haruhisa Mita, PhDb, Masami Taniguchi,

Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic.

Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis Teruo Shiomori, MDa, Shin-ichi Yoshida, MD, PhDb,

IgG4 production is confined to human IL-10–producing regulatory B cells that suppress antigen-specific immune responses Willem van de Veen, MSc, Barbara.

News & Notes Journal of Allergy and Clinical Immunology

Antihistamine premedication in specific cluster immunotherapy: A double-blind, placebo- controlled study Lone Nielsen, MD, Claus R. Johnsen, MD, Holger.

The kinetics of change in cytokine production by CD4+ T cells during conventional allergen immunotherapy Suwat Benjaponpitak, MDa*, Amy Oro, MDa*, Peter.

Pascal Chanez, MDa, Antonio M

Presentation transcript:

Modulation of T-cell response to phospholipase A2 and phospholipase A2–derived peptides by conventional bee venom immunotherapy Regine Kämmerer, MDa,b, Yolande Chvatchko, PhDa,b, Alexander Kettnera,b, Nathalie Dufoura, Giampietro Corradin, PhDb, François Spertini, MDa Journal of Allergy and Clinical Immunology Volume 100, Issue 1, Pages 96-103 (July 1997) DOI: 10.1016/S0091-6749(97)70200-8 Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 1 CD8−PBMC response to PLA2 and its three LPs (1 to 60, 51 to 99, and 90 to 134) mapping whole PLA2 (10 μg/ml each or as a mixture of three LPs) at initiation of VIT (DO) and 14 weeks later (W14). Results are expressed as individual stimulation indices (open circles) and as the median (black cross). Statistical analysis was performed with the paired Wilcoxon signed-rank test. Responses to the TT control showed no significant variation during this time period. NS, Not significant; *, p < 0.05; **, p < 0.01. Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 2 CD8−PBMC proliferation in response to peptides 51 to 99 and 90 to 134 at initiation of VIT (DO), at week 3 (W3), at week 6 (W6), and at the end of the incremental dose period (W14). Results show the distribution of stimulation indices from individual subjects as boxes (percentile 25, lower border; median, bold line; percentile 75, upper border) and whiskers (percentile 10, lower whisker; percentile 90, upper whisker). Statistical analysis between stimulation indices for each peptide at indicated time points was done with KruskaI-Wallis nonparametric analysis of variance tests (p < 0.01). Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 3 CD8−PBMC responses from group I and group II patients to PLA2 and its three LPs. Results are expressed as the distribution of individual data (stimulation indices) as described in Fig. 2. Statistical analysis between results from group I and II was done with the unpaired Wilcoxon signed-rank test. Responses to TT control showed no significant variation between groups. NS, Not significant; *, p < 0.05; ***, p < 0.001. Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 4 Serum levels (in kU/L) of specific IgE against whole BV (A and C) and PLA2 (B and D) in group I patients (A and B) at initiation of VIT (DO) and 14 weeks later (W14), and in group II patients (C and D) at initiation of VIT and after 3 to 5 years of VIT. L. Statistical analysis was done with a paired Student's t test NS; Not significant, *, p < 0.05; **, p < 0.01). Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 4 Serum levels (in kU/L) of specific IgE against whole BV (A and C) and PLA2 (B and D) in group I patients (A and B) at initiation of VIT (DO) and 14 weeks later (W14), and in group II patients (C and D) at initiation of VIT and after 3 to 5 years of VIT. L. Statistical analysis was done with a paired Student's t test NS; Not significant, *, p < 0.05; **, p < 0.01). Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 4 Serum levels (in kU/L) of specific IgE against whole BV (A and C) and PLA2 (B and D) in group I patients (A and B) at initiation of VIT (DO) and 14 weeks later (W14), and in group II patients (C and D) at initiation of VIT and after 3 to 5 years of VIT. L. Statistical analysis was done with a paired Student's t test NS; Not significant, *, p < 0.05; **, p < 0.01). Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 4 Serum levels (in kU/L) of specific IgE against whole BV (A and C) and PLA2 (B and D) in group I patients (A and B) at initiation of VIT (DO) and 14 weeks later (W14), and in group II patients (C and D) at initiation of VIT and after 3 to 5 years of VIT. L. Statistical analysis was done with a paired Student's t test NS; Not significant, *, p < 0.05; **, p < 0.01). Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 5 Serum levels of specific IgG (A and C) and IgG4 (B and D) against whole BV in group I patients (A and B) at initiation of VIT (DO) and 14 weeks later (W14) and in group II patients (C and D) at initiation of VIT and after 3 to 5 years of VIT. Results are reported as percentage of a reference serum sample. Statistical analysis was done with a paired Student's t test NS; not significant; *, p < 0.05. Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 5 Serum levels of specific IgG (A and C) and IgG4 (B and D) against whole BV in group I patients (A and B) at initiation of VIT (DO) and 14 weeks later (W14) and in group II patients (C and D) at initiation of VIT and after 3 to 5 years of VIT. Results are reported as percentage of a reference serum sample. Statistical analysis was done with a paired Student's t test NS; not significant; *, p < 0.05. Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 5 Serum levels of specific IgG (A and C) and IgG4 (B and D) against whole BV in group I patients (A and B) at initiation of VIT (DO) and 14 weeks later (W14) and in group II patients (C and D) at initiation of VIT and after 3 to 5 years of VIT. Results are reported as percentage of a reference serum sample. Statistical analysis was done with a paired Student's t test NS; not significant; *, p < 0.05. Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 5 Serum levels of specific IgG (A and C) and IgG4 (B and D) against whole BV in group I patients (A and B) at initiation of VIT (DO) and 14 weeks later (W14) and in group II patients (C and D) at initiation of VIT and after 3 to 5 years of VIT. Results are reported as percentage of a reference serum sample. Statistical analysis was done with a paired Student's t test NS; not significant; *, p < 0.05. Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 6 Cytokine secretion by short-term T cell lines from patients hypersensitive to BV, which were stimulated with PMA/ionomycin for 24 hours: lines were raised against a mixture of three LPs mapping PLA2, at initiation of VIT (DO), after 14 weeks of VIT (W14) (group I patients), and at the end of VIT (>3 years) (group II patients). Solid bars indicate the median of cytokine secretion or cytokine ratio from five individual lines. Statistical analysis was done with a nonparametric analysis of variance test * p < 0.05, DO vs > 3 years). Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 6 Cytokine secretion by short-term T cell lines from patients hypersensitive to BV, which were stimulated with PMA/ionomycin for 24 hours: lines were raised against a mixture of three LPs mapping PLA2, at initiation of VIT (DO), after 14 weeks of VIT (W14) (group I patients), and at the end of VIT (>3 years) (group II patients). Solid bars indicate the median of cytokine secretion or cytokine ratio from five individual lines. Statistical analysis was done with a nonparametric analysis of variance test * p < 0.05, DO vs > 3 years). Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 6 Cytokine secretion by short-term T cell lines from patients hypersensitive to BV, which were stimulated with PMA/ionomycin for 24 hours: lines were raised against a mixture of three LPs mapping PLA2, at initiation of VIT (DO), after 14 weeks of VIT (W14) (group I patients), and at the end of VIT (>3 years) (group II patients). Solid bars indicate the median of cytokine secretion or cytokine ratio from five individual lines. Statistical analysis was done with a nonparametric analysis of variance test * p < 0.05, DO vs > 3 years). Journal of Allergy and Clinical Immunology 1997 100, 96-103DOI: (10.1016/S0091-6749(97)70200-8) Copyright © 1997 Mosby, Inc. Terms and Conditions